CA-PERSONALIS,-INC.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Biomarkers Week Online 2021.
The presentation , titled “ImmunoID NeXT Platform® for comprehensive tumor immunogenomics and advanced biomarker discovery,” will describe the Personalis universal cancer immunogenomics platform, ImmunoID NeXT ™. Erin Newburn, MS, PhD, will present for Personalis. Dr. Newburn will provide an overview of the platform, which combines highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics to provide a multidimensional view of the tumor and the tumor microenvironment (TME) from a single sample preparation. Dr. Newburn will review a case study in a cohort of 51 late-stage melanoma patients that demonstrates how the integration of neoantigen burden, HLA LOH, and Antigen Presentation Machinery (APM) mutational data formed a composite biomarker that more accurately predicted response to checkpoint blockade than other markers. Additionally, Dr. Newburn will highlight our NeXT Liquid Biopsy™, an exome-wide liquid biopsy approach combined with ImmunoID NeXT, to further explore critical areas of tumor biology.
ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The ImmunoID NeXT Platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.
Personalis is a co-sponsor of Biomarkers Week and will have representatives available to answer questions about the company’s cancer immunogenomics capabilities.
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency, and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue and matched blood sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc ).
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the Personalis NeXT Platform, Personalis’ business opportunities, leadership, plans, vision or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005432/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EV Group Strengthens Its European Presence With the Acquisition of Cornelius Polska22.1.2026 13:19:00 CET | Press release
Eigenmann & Veronelli Group (“EV Group”), a leading distributor and manufacturer of specialty chemicals and food ingredients, has signed an agreement to acquire the majority shareholding in Cornelius Polska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122961168/en/ Photographed (left to right): Ludovico Balbo di Vinadio, Shareholder and Deputy Chairman, EV Group; Piotr Wasilewski, General Manager, Cornelius Polska Sp. z. o. o.; Cristina Colombo, Chief Financial Officer, EV Group; Dr Neville Prior, Group Chairman, Cornelius Group plc; Gabriele Bonomi, Chief Executive Officer, EV Group Established in Poland in 2007 and headquartered in Warsaw, Poland, Cornelius Polska is a well‑established distributor of specialty chemicals, serving as a key partner to international suppliers, and a broad and diverse customer base. With operations firmly rooted in Poland, the company is active in the beauty & personal care, food, and sev
Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES22.1.2026 13:00:00 CET | Press release
Concept Medical Inc., a global pioneer in innovative drug delivery technology, is proud to announce the successful enrollment of the first patients in the STARS DAPT (ST-Segment Elevation Myocardial InfArction treated with a Polymer-Free Sirolimus-based NanocarrieR Eluting Stent and a P2Y12 inhibitor-based Single Antiplatelet Strategy after a Short Dual Antiplatelet Therapy versus conventional Dual AntiPlatelet Therapy) randomized controlled trial. This trial marks a significant milestone in evaluating the breakthrough technology of polymer free drug eluting stent (DES) for the treatment of STEMI patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121338054/en/ Concept Medical announces first patient enrollment in the STARS DAPT randomized clinical trial evaluating Abluminus™ NP polymer-free DES The first four patients were enrolled by (Professor Barbara Stähli and her team at the University Hospital of Zurich in Swi
SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing22.1.2026 12:00:00 CET | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to continue its listing on the Nasdaq Stock Market, subject to stated conditions focused on timely completion of its financial audit and remediation of filing delinquencies. Under the Panel’s decision, SINOVAC must, on or before May 11, 2026, demonstrate compliance with Nasdaq Listing Rule 5250(c)(1) and Listing Rule 5250(c)(2) by completing filings of its annual report for the year ended December 31, 2024 on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of year 2025 on Form 6-K. As disclosed on January 4, 2026, the Company has engaged Zhonghua Certified Public Accountants LLP (“Zhonghua”) as its independent registered public accounting firm. SINOVAC is working diligently with Zhonghua to complete the required audit and t
Sisvel Launches Wi-Fi Multimode Patent Pool22.1.2026 12:00:00 CET | Press release
Ten patent owners establish licensing solution covering Wi-Fi 6 and Wi-Fi 7 standards Sisvel has launched a groundbreaking Wi-Fi Multimode patent pool offering access to standard essential patents owned by 10 Wi-Fi 6 and Wi-Fi 7 technology leaders. As the successor to Sisvel’s highly successful Wi-Fi 6 patent pool – which, over a three-year period, closed agreements with nearly 40 companies, including Acer, Netgear, Cisco and HP – the new programme offers an efficient way to access essential Wi-Fi rights for years to come. The 10 founding patent owners in the Wi-Fi Multimode programme are Huawei, KPN, Mitsubishi Electric, Orange, Panasonic, Philips, Aegis 11 SA (a Sisvel affiliate), SK Telecom, Wilus and ZTE. In addition, Sony Group Corporation has taken a licence under the Wi-Fi Multimode programme. This early agreement with a sophisticated and globally recognised Wi-Fi leader and implementer underlines the pool’s strong value proposition and the efforts made by Sisvel to engage with
Otto Group Enables AI-driven Intelligent Robot Coordination With the Digital Twin Developed by Roboverse Reply22.1.2026 11:52:00 CET | Press release
Reply [EXM, STAR: REY] is supporting the global retailer Otto Group in implementing a central, AI-driven virtual control system for intelligent robotic orchestration. Developed as part of a strategic collaboration between Otto Group, Reply, and NVIDIA, the "Robotic Coordination Layer" enables the training, simulation, and orchestration of autonomous mobile robots and stationary systems, accelerating delivery times and enhancing service levels This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122331989/en/ This initiative with the Otto Group and NVIDIA underscores Roboverse Reply’s role as an implementation partner for AI-powered robotics and Physical AI in logistics. At the centre is a high-fidelity digital twin, serving as a precise replica of the warehouse environment and accurately representing the positions, movements, and interactions of all robotic systems. Developed thanks to Roboverse Reply’s expertise in robotic int
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom